Movement Alert｜GRAIL, Inc. Intraday Rise 5.61% in Regular Trading, FDA review progress and UBS target hike support sentiment

Market Focus10-26

On October 26, GRAIL, Inc. recorded an Intraday Rise of 5.61% in Regular Trading, trading at $139.77 per share, with turnover of $21.8915 million.

The move follows continued market digestion of a favorable FDA advisory committee outcome for Galleri and a subsequent UBS target-price increase to $175 from $105, while maintaining a buy rating.

Earlier disclosures showed the FDA panel voted 10-0 on safety, 6-4 on efficacy, and 7-2 with one abstention on benefit-risk for Galleri in adults aged 50 or older. Commentary around the review indicated the debate had narrowed toward product positioning and labeling rather than core safety or analytical-performance concerns, reinforcing expectations for regulatory progress and commercialization potential.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment